Xalud has assembled a world class Scientific Advisory Board.
Linda Watkins, PhD: Co-Chair
Dr. Watkins is a University of Colorado Distinguished Professor of Psychology and Neuroscience at the University of Colorado Boulder. A co-founder of Xalud, she is a world-renown leader in glia research and the neurological applications of glial attenuation, with a focus on alleviation of chronic pain. She is the recipient of the highest award for distinguished basic science research from the American Pain Society, the 2010 John Liebeskind Pain Management Research Award from the American Academy of Pain Management and the 2010 Prince of Asturias prize for scientific and technical research. She has over 300 peer-reviewed publications including articles in Nature, Science, Nature Neuroscience, and Journal of Neuroscience. She is the thought leader behind XT-150, having received over $2 million in NIH grants supporting six generations of IL-10 gene therapy research culminating in XT-150.
John Forsayeth, PhD: Co-Chair
Dr. Forsayeth, a co-founder of Xalud, is an expert in gene therapy technologies and translational research. He currently is a Professor of Neurosurgery at UCSF and was formerly Director of Neurobiology at Avigen, Inc. He has also held senior research positions at Neurex and Elan Pharmaceuticals. He has been a principal investigator or co-investigator on NIH-supported gene therapy grants, and is a co-author of over 60 peer-reviewed papers and book chapters. He has been a key collaborator with the Watkins laboratory in the development of IL-10 gene therapy since 2003.